A year after missing on a trial endpoint, Travere Therapeutics can breathe a sigh a relief. | A year after missing on a trial ...

Travere Therapeutics TVTX announced that the FDA granted full approval to its oral non-immunosuppressive drug Filspari ...

The company had focused its resources on Filspari’s launch in IgAN after the US FDA snubbed the therapy in another rare ...

progressive kidney disease and a leading cause of kidney failure due to glomerular disease. The FDA early last year had granted conditional approval of the drug, subject to confirmatory study results.

Patients will be able to get a 10 minute injection of the Roche drug, instead of an hours-long infusion. Novartis already has ...

FDA grants full approval to Filspari to slow kidney function decline in adults with primary IgA nephropathy at risk for disease progression.

The PDUFA date refers to the deadline set by the US Food and Drug Administration for reviewing drug applications.

The U.S. Food and Drug Administration has allowed the expanded use of Johnson & Johnson's drug, Tremfya, to treat adults with ...

Returning to Boston this December, the 4th annual Rare & Genetic Kidney Disease Drug Development Summit will unite 30+ experts speakers including Novartis, FDA, XORTX Therapeutics, Walden Biosciences, ...

Staff reviewers at the U.S. Food and Drug Administration said on Wednesday a confirmatory trial did not show the ...

Bayer’s Kerendia, at the center of a $3 billion sales forecast, reduced the risk of cardiovascular death and heart failure in ...

One year after reporting a split result on Merck’s Welireg in a key phase 3 trial, the song remains the same for the kidney ...